Pediatric Exclusivity Will Not Irreparably Harm Generics, Judge Rules
This article was originally published in The Tan Sheet
Executive Summary
Exclusivity extensions under the FDA Modernization Act's pediatric provisions will not cause "irreparable harm" to generic drug manufacturers, D.C. federal court Judge James Robertson rules in an April 20 decision denying a generics industry motion for a preliminary injunction.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning